Famotidine
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Famotidine: From Peptic Ulcer Disease to Duodenogastric Reflux
One-Sentence Summary
Famotidine is a histamine H2-receptor antagonist historically used to treat peptic ulcer disease and acid-related gastrointestinal conditions. The TxGNN model predicts it may also be effective for Duodenogastric Reflux, with a prediction score of 99.99%, though currently only 2 publications and no registered clinical trials directly support this specific direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Peptic Ulcer Disease / Acid-related GI disorders (based on known drug class; no TFDA/India label text available — see Data Gap DG001) |
| Predicted New Indication | Duodenogastric Reflux |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L3 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold (source data labels this “Research Question” stage — S1) |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (Data Gap DG002). Based on known information, Famotidine belongs to the histamine H2-receptor antagonist class, and its efficacy in acid-related peptic ulcer disease is well established through decades of clinical use.
Duodenogastric reflux (bile/duodenal content refluxing into the stomach) is mechanistically distinct from simple gastric acid hypersecretion, so the applicability of an H2-antagonist is less direct than in classic acid-peptic disease. Per the model’s own rationale: acid suppression may reduce symptoms associated with concurrent acidic reflux, but the mechanistic link to bile/duodenogastric reflux itself is indirect, since neutralizing bile-mediated mucosal injury is not the primary pathway of H2-receptor blockade.
Given this indirect mechanistic link, and the fact that only observational/small non-RCT literature exists for this specific indication, the prediction should be treated as a research hypothesis rather than a near-term repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12532466 | 2003 | Cohort (ICU patients) | World Journal of Gastroenterology | Investigated famotidine’s effect on gastroesophageal reflux (GER) and duodeno-gastro-esophageal reflux (DGER) in critically ill patients, exploring possible mechanisms and relevant risk factors. |
| 16259441 | 2004 | Review / small non-English study | Eksperimental’naia i klinicheskaia gastroenterologiia | Evaluated famotidine 20 mg BID at early stages of gastroduodenal reflux disease (Savary-Miller grade 0–1) via clinical and endoscopic assessment. |
India Market Information
Famotidine is currently not registered or marketed in India (0 registrations on file).
Safety Considerations
Drug Interactions: 639 documented interactions on record (source: DDInter). Representative Moderate-level interactions include Abiraterone, Acalabrutinib, Tramadol, Abarelix, Acetohexamide, Adenosine, Salbutamol, Aminophylline, Amiodarone, Amisulpride, Amitriptyline, Amoxapine, Anagrelide, Apalutamide, Apomorphine, Arformoterol, and Aripiprazole. Minor-level interactions include Alendronic acid and Aluminum hydroxide.
(Key warnings and contraindications are not yet available — see Data Gap DG001 below.)
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but for duodenogastric reflux specifically the evidence base is limited to two older, non-RCT publications with no registered clinical trials, and the mechanistic link (H2-blockade vs. bile-mediated reflux injury) is indirect. This does not yet meet the bar to proceed.
To proceed, the following is needed:
- TFDA/India regulatory package insert (warnings, contraindications) — currently blocking (Data Gap DG001)
- Confirmed mechanism of action data from DrugBank — currently high-impact gap (Data Gap DG002)
- Prospective or controlled trials evaluating famotidine specifically in duodenogastric/duodeno-gastro-esophageal reflux populations
- Note: within this same evidence pack, other predicted indications for famotidine — peptic ulcer disease (L1, multiple completed Phase 3/4 RCTs), active peptic ulcer disease (L1), and gastrojejunal/marginal ulcer (L2, direct Phase 4 RCT evidence) — show substantially stronger, more actionable evidence and may warrant prioritization over duodenogastric reflux.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.